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Letter to the Editor

J Clin Med Res. 2021;13(2):130-132

Voxelotor Modulates the Analgesic Effect of
Certain Opioids
Samir K. Ballas

To the Editor
Voxelotor (Oxbryta, Global Blood Therapeutics (GBT) 440)
was developed by GBT for the treatment of sickle cell disease
(SCD) in adults and children 12 years of age and older. It exerts its action by binding to the amino acid terminal of both α
chains of hemoglobin (Hb). This, in turn, prevents or decreases
the polymerization of hemoglobin S (HbS) by increasing Hb
oxygen affinity. The efficacy and safety of voxelotor in SCD
was evaluated in a phase III randomized, double-blind, placebo-controlled multicenter trial in combination with and without Hounsfield unit (HU) (Heart Outcome Prevention Evaluation Trial (HOPE Trial)) [1]. It was approved by the United
States Food and Drug Administration on November 19, 2019
[2]. The approval was accelerated based on increase in Hb.
Continued approval for this indication may be contingent upon
verification and description of clinical benefit in confirmatory
trial(s).
Efficacy was based on Hb response rate defined as Hb increase of > 1 g/dL from baseline to week 24 in patients treated
with voxelotor 1,500 mg versus placebo. The response rate
for voxelotor 1,500 mg was 51.1% (46/90) compared to 6.5%
(6/92) in the placebo group (P < 0.001).
Recommended dosage of voxelotor is 1,500 mg orally
once daily with or without food. Recommended dosage for severe hepatic impairment is 1,000 mg orally once daily with or
without food [2].
From the pharmacokinetic point of view, in vitro and in
vivo studies showed that voxelotor is excessively metabolized
through phase I metabolism that includes the utilization of cytochrome P450 (CYP450) enzymes (oxidation and reduction),
phase II (glucuronidation) and a combination of both phases.
Oxidation of voxelotor is mediated mostly by CYP3A4 enzyme with minor contributions from CYP2CI9, CYP2B6 and
CYP2C9 [2]. This multiplicity of metabolic pathways renders
voxelotor vulnerable to drug-drug interactions where other
dugs affect its metabolism or, conversely, where voxelotor
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itself affects the metabolism of other drugs. Thus, the daily
dose of voxelotor has to be adjusted in the presence of strong
CYP3A4 inhibitors, to 1,000 mg once daily because inhibition of CYP3A4 maintains a relatively higher concentration of
voxelotor in the blood. Conversely, inducers of CYP3A4 result
in rapid degradation of voxelotor into inactive metabolites that
require increasing the dose to 2,500 mg once daily [2]. Potent
inducers of CYP3A4 that may be prescribed to patients with
SCD include barbiturates, carbamazepine, phenytoin, dexamethasone and rifampin. Potent inhibitors of CYP3A4 often
prescribed to patients with SCD include cimetidine, fluoroquinolones, selective serotonin reuptake inhibitors, quinine, macrolides and calcium-channel blockers (diltiazem).
The plot thickens if the metabolic profile of opioids is
brought into the picture. The significance of the role of opioids to manage the pain of the acute painful vaso-occlusive
crisis (VOCs) becomes evident from the recent advances in
understanding the pharmacogenomics of drugs in general including the opioids [3]. The metabolism of certain opioids also
includes phase I pathway shown in Table 1. Phase I involves
the CYP450 enzymes whereas glucuronidation is the major
metabolic pathway in phase II metabolism. Phase I metabolism of opioids involves primarily the CYP3A4 and CYP2D6
enzymes. The CYP3A4 enzyme metabolizes more than 50%
of all drugs; consequently, opioids metabolized by this enzyme
have a high risk of drug-drug interactions [4]. The CYP2D6
enzyme metabolizes fewer drugs and is therefore associated
with an intermediate risk of drug-drug interactions [4]. The
CYP3A4 enzyme is the primary metabolizer of fentanyl and
oxycodone, although normally some oxycodone undergoes
CYP2D6-mediated metabolism to oxymorphone (Table 1) [4].
Tramadol undergoes both CYP3A4-mediated and CYP2D6mediated metabolism. Methadone is primarily metabolized by
CYP3A4 and CYP2B6. CYP2C8, CYP2CD19, CYP2D6, and
CYP2C9 also contribute in variable degrees to its metabolism
[5]. Since voxelotor itself inhibits CYP3A4, the co-administration of certain opioids (hydrocodone, oxycodone, fentanyl
and methadone) shown in Table 1 will increase their analgesic
effect and/or their side effects especially after multiple dosing. Figure 1 shows an example of the effect of inhibiting the
CYP3A4 enzyme on the analgesic efficacy of fentanyl. The
same applies to oxycodone, methadone and tramadol.
The plot thickens further considering the complexity of
the pharmacogenomics of the CYP450 system where the enzymes may be deleted, mutated, duplicated or even triplicated
[6]. Human CYP consists of 21 currently described families
and 20 subfamilies coded by 57 genes and 58 pseudogenes [7].
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Table 1. Metabolism of Certain Opioids Used in Sickle Cell Disease by the Cytochrome P450 Enzymes
Opioid

CYP450 enzyme

Active metabolite

Codeine

CYP2D6

Morphine, hydrocodone

Hydrocodone

CYP2D6, 3A4

Hydromorphone

Oxycodone

CYP2D6, 3A4

Oxymorphone

Fentanyl

CYP3A4

None

Methadone

CYP2D6, 3A4, 2C8, 2C9, 2C19, 2B6, 1A2

None

Tramadol

CYP2D6, 3A4, 2B6

None

Adapted from Ballas S. K. Sickle Cell Pain, Second Edition. Washington DC: International Association for the Study of Pain; 2014. CYP450: cytochrome P450.

The CYP isoforms 1, 2, and 3 are responsible for the majority
of hepatic drug metabolism. Of these, CYP2C9 and CYP2D6
are involved in the metabolism of several drugs used for pain
control including opioid and nonopioid analgesics. Phase I metabolism of opioids involves primarily the CYP3A4 and CYP2D6 enzymes. The CYP3A4 enzyme metabolizes more than
50% of all drugs; consequently, opioids metabolized by this
enzyme have a high risk of drug-drug interactions. Accordingly, medications used in addition to opioids may enhance or
inhibit the metabolism of the opioid in question.
In the phase III trial of voxelotor [1], a VOC during treatment was defined, among other things, as pain that required
treatment with oral or parental opioids, ketorolac, or other
analgesics. Usually opioids are used routinely in most cases. However, the specific opioids used were not mentioned.
Thus, we do not know if the opioids used belonged to phase I
CYP450 or to phase II glucuronidation. This might have created a confounding factor.
Thus, if the voxelotor group received more opioids metabolized by CYP3A4 shown in Table 1, the chances are that
they may have achieved better pain control than the placebo
group and hence, requiring less intake of more opioids. The
voxelotor (HOPE) trial did not mention the amount of opioid
intake by the groups involved in the study.

If the voxelotor group did indeed consume fewer opioids,
this would have been considered a positive clinical response.
Future trials should consider the specific opioids used especially if the drug being studied inhibits certain CYP450 enzymes shown in Table 1. It is highly recommended that future
such studies limit the use of opioids to opioids phase II drugs
such as morphine or hydromorphone.
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Figure 1. Effect of CYP3A4 enzyme on the metabolism of fentanyl. Equation A shows how CYP3A4 enzyme usually metabolizes
fentanyl by oxidizing it to inactive metabolites and hence, decreases its concentration in blood. Equation B shows that inhibition
of CYP3A4 decreases the oxidation of fentanyl to inactive metabolites and hence, maintains its concentration in blood to maintain
or increase its analgesic effect.
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